Amtagvi's Real-World Success Redefines Advanced Melanoma Treatment

SAN CARLOS, CA – February 05, 2026 – New real-world data for Amtagvi, a first-of-its-kind cell therapy, is showing unprecedented effectiveness in patients with advanced melanoma, particularly when used earlier in the treatment process. The results, presented by Iovance Biotherapeutics, suggest a potential paradigm shift in how oncologists may approach this deadly skin cancer, offering renewed hope for thousands of patients.

The data, unveiled in an oral presentation at the 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), demonstrates that the therapy’s performance in everyday clinical practice not only meets but exceeds the results seen in the pivotal trials that led to its approval.

A New Benchmark in Melanoma Treatment

The retrospective study analyzed outcomes for 41 patients with advanced melanoma treated with commercial Amtagvi at four authorized U.S. centers. The results were striking: physicians reported a confirmed objective response rate (ORR) of 44%, meaning nearly half of the patients saw a significant reduction in their tumors. Furthermore, the disease control rate (DCR), which includes patients whose cancer stabilized, reached 73%.

These figures represent a significant improvement over the 31% ORR from the C-144-01 clinical trial, which supported the U.S. Food and Drug Administration's (FDA) accelerated approval of Amtagvi in February 2024. The strong performance in a real-world setting provides crucial validation that the therapy’s benefits translate from the highly controlled environment of a clinical trial to diverse, real-life patient populations.

Amtagvi, known generically as lifileucel, is the first and only FDA-approved tumor-infiltrating lymphocyte (TIL) therapy for a solid tumor. It offers a one-time treatment for patients whose advanced melanoma has progressed despite prior treatment with anti-PD-1 immunotherapies and, for those with a specific genetic marker, targeted BRAF inhibitors.

"The real-world response rate builds on existing clinical data and supports consideration of lifileucel as soon as possible after immune checkpoint inhibitor treatment," stated Dr. Lilit Karapetyan of the H. Lee Moffitt Cancer Center & Research Institute, one of the physicians involved in the data collection. "I am encouraged by the potential for an increasing number of patients to benefit as adoption of TIL therapy continues."

The Compelling Case for Earlier Intervention

The most compelling finding from the new data is the dramatic increase in efficacy when Amtagvi is used earlier. The study stratified patients by the number of prior treatments they had received. For the 23 patients who received Amtagvi after two or fewer lines of therapy, the objective response rate soared to 52%. In contrast, for the 18 patients who received it after three or more lines of therapy, the ORR was 33%.

This difference strongly suggests that the therapy is more potent when a patient’s immune system is less compromised by multiple rounds of taxing cancer treatments. This finding could reshape clinical strategy, encouraging oncologists to consider this powerful, personalized therapy sooner rather than holding it as a last resort. Advanced melanoma remains a significant unmet need, with more than 8,000 deaths annually in the U.S. and over half of patients seeing their disease progress within a year of starting standard first-line care.

"The real world Amtagvi data with impressive response rates, paired with unprecedented five-year durability and survival data, demonstrate a best-in-class profile and better outcomes in patients treated earlier," said Daniel Kirby, Chief Commercial Officer of Iovance. The company has previously published data showing a five-year overall survival rate of 20% from its clinical trial, a remarkable figure for this heavily pre-treated population.

From Trial to Reality: The Complex Patient Journey

The success of Amtagvi is a landmark achievement for personalized medicine, but it involves a complex and logistically intensive process. Unlike conventional drugs, each dose of Amtagvi is unique to the individual patient.

The journey begins with the surgical removal of a portion of the patient’s tumor. This tissue is then shipped to a centralized manufacturing facility, where the patient’s own tumor-infiltrating lymphocytes—specialized T cells that have already recognized and invaded the cancer—are isolated. These cells are then multiplied by the billions in a process that takes approximately 34 days.

Once the personalized cell therapy is ready, it is shipped back to the patient's authorized treatment center. The patient is typically hospitalized and undergoes a course of lymphodepleting chemotherapy to make space in their body for the new army of cancer-fighting cells. Following the one-time intravenous infusion of Amtagvi, patients may receive up to six doses of a supportive drug, IL-2, to encourage the TIL cells to proliferate and attack the cancer. Due to the intensity of the regimen and potential side effects, patients must remain near the treatment center for several weeks for close monitoring.

Commercial Hurdles and Market Momentum

The high-touch, individualized nature of Amtagvi comes with significant costs and logistical challenges. The therapy carries a list price of $515,000, not including the associated costs of surgery, hospitalization, and supportive care. This has raised concerns about patient access and reimbursement hurdles.

However, Iovance is making a strong commercial push, backed by this compelling new data. The company has reaffirmed its 2025 revenue guidance for Amtagvi at $250 million to $300 million in its first full year on the market. It is also working to streamline production and reduce costs by centralizing manufacturing at its Iovance Cell Therapy Center (iCTC) in Philadelphia, which has the capacity to serve several thousand patients annually.

The robust real-world data serves as a powerful tool to justify the therapy’s value to both clinicians and payers. The demonstration of superior efficacy, particularly in earlier treatment lines, strengthens the argument that the upfront investment can lead to durable, long-term responses, potentially saving costs and, more importantly, lives down the line.

To further solidify Amtagvi's role in cancer care, Iovance is conducting the TILVANCE-301 Phase 3 clinical trial. This study is evaluating the therapy in frontline advanced melanoma, a move that could position this revolutionary treatment as a primary option for patients, fundamentally altering the standard of care for this devastating disease.